Unraveling the Role of HDAC Inhibitors in Targeted Cancer Therapy for Enhanced Anticancer Drug Design

Abstract

Cancer is a deadlier disease now a day. Heterocyclic compounds are playing a crucial role for the treatment of cancer. Numerous anti-cancer agents are available in market which contain heterocyclic ring. Among the heterocyclic ring thiadizole is of great interest in the recent era due to their potential anti-cancer activity. Histone deacetylases (HDAC) is a crucial player in oncogenesis, proliferation, differentiation, DNA repair, up-regulation of silenced tumor suppressors, and tumor progression. Therefore, it is become a promising target for cancer drug design.  This review explores the chemical structure of thiadiazole derivatives, anticancer activity and binding analysis of HDAC inhibitors from the year 2019 to 2024. Through comprehensive examination of thiadiazole scaffold containing derivatives. Overall, this review underscores the pivotal role of HDAC inhibition and guiding the rational design of next-generation anticancer agents targeting this pathway.